A new clinical trial involving cagrilintide was listed as recruiting on October 19, 2026. The study, registered as NCT07607587, is titled "Evaluation of the Tolerability of Cagrilintide in Participants Not Tolerating GLP-1-RA Therapies Due to Gastrointestinal Adverse Events." It is designated a Phase 1 trial. According to the registry entry, the trial's status is currently listed as recruiting. Cagrilintide remains an unapproved compound under research and is not approved for clinical use outside of studies like this one. The trial focuses on participants who previously did not tolerate GLP-1 receptor agonist therapies because of gastrointestinal adverse events. No outcomes, safety findings, or efficacy data have been reported for this trial as of the listed date. The update reflects only the trial's recruitment status and design as registered. Further details on trial design, eligibility, or results may be added as the study progresses. Readers interested in background on this compound can consult the compound overview for additional context.
Phase 1 Trial of Cagrilintide Begins Recruiting as of Oct 19, 2026
See the full cagrilintide overview
Source: https://clinicaltrials.gov/study/NCT07607587